Author

V. M. Pogorelov

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Assay:behavioral assay· 1 Organism:mouse· 1 Organism:non-human primate· 1 Organism:rat· 1

Frequent Co-Authors

R. M. Rodriguiz· 2 shared W. C. Wetsel· 2 shared A. E. Dulcey· 1 shared A. N. Nilson· 1 shared B. L. Roth· 1 shared D. R. Sibley· 1 shared H. D. Lim· 1 shared J. H. Woods· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

R. M. Rodriguiz

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The G protein biased serotonin 5-HT 2A receptor agonist lisuride exerts anti-depressant drug-like activities in mice

V. M. Pogorelov, R. M. Rodriguiz, B. L. Roth, W. C. Wetsel

This study shows that lisuride, a G protein biased 5-HT2AR agonist, produces anti-depressant effects in mice without hallucinogenic actions, with limited involvement of β-arrestin pathways.

bioRxiv · Jun 1, 2023 · PreprintPharmacology & Toxicology

Identification and Characterization of ML321: a Novel and Highly Selective D2 Dopamine Receptor Antagonist with Efficacy in Animal Models that Predict Atypical Antipsychotic Activity

R. B. Free, A. N. Nilson, N. M. Boldizsar, T. Doyle, R. M. Rodriguiz, V. M. Pogorelov, M. Machino, K. H. Lee, J. W. Bertz, J. Xu, H. D. Lim, A. E. Dulcey, R. H. Mach, J. H. Woods, J. R. Lane, , D. R. Sibley

This paper develops ML321, a highly selective D2 dopamine receptor antagonist, showing efficacy in animal models predictive of atypical antipsychotic activity with fewer side effects.

bioRxiv · Nov 14, 2022Pharmacology & Toxicology